Merus N.V. MRUS
Jan 2, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- 0.00%
- 1 year
- +112.77%
- Market cap
- 6.83B
- Revenue (ttm)
- 56.61M
- Shares out
- 75.85M
- Forward P/E
- -17.65
- YTD return
- 0.00%
- 1-year return
- +112.77%
- Volume
- 2.72M
- Open
- 90.00
- Previous close
- 90.00
- Day's range
- 90.00 – 90.00
- Beta
- 1.06
- Analysts
- Hold
- Price target
- 97.00 (+7.8%)
2Y +36.87 (+69.40%)
Key statistics
- Enterprise value
- 6.20B
- PEG ratio
- 0.00
- Price / sales
- 120.59
- Price / book
- 8.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 3.20%
- Free cash flow
- -174.43M
- Total cash
- 635.93M
- Total debt
- 12.32M
- Return on equity
- -51.57%
- Short % of float
- 1.08%
- 50-day average
- 95.41
- 200-day average
- 69.34
Analyst view
Consensus: hold
- Strong buy0
- Buy1
- Hold9
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.99344.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 30, 2025 | Guggenheim | down | Buy | Neutral |
| Sep 30, 2025 | Canaccord Genuity | down | Buy | Hold |
| Sep 30, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Sep 30, 2025 | UBS | down | Buy | Neutral |
| Sep 30, 2025 | LifeSci Capital | down | Outperform | Market Perform |
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- merus.nl
News
10 Health Care Stocks Whale Activity In Today's Session 
Genmab To Offer $1.5B Of Senior Secured Notes Due 2032 And $1B Of Senior Unsecured Notes Due 2033, The Company Also Launched The Syndication Of A New $2B Senior Secured Term Loan In Addition To A $1B Senior Secured Term Loan Facility And $500M Senior Secured Revolving Credit Facility To Finance The Merus Acquisition 
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings 
12 Health Care Stocks Moving In Monday's Intraday Session 
Tilray Brands, SNDL, Innoviz Technologies, Pony AI And Other Big Stocks Moving Higher On Monday 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket 
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? 
D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Your note
Sign in to keep a note on MRUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKKER LEX B H | Officer | Conversion of Exercise of derivative security | Jul 1, 2021 | 15,668 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2021 | 0 |
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 7, 2021 | 0 |
| DE KRUIF JOHN | Chief Technology Officer | Sale | Aug 11, 2021 | 15,282 |
| GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 25, 2025 | 0 |
| IWICKI MARK T. | Director | Conversion of Exercise of derivative security | Apr 13, 2023 | 73,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 5.77% | 4,373,770 | 393.64M | Sep 29, 2025 |
| Avoro Capital Advisors LLC | 4.67% | 3,542,500 | 318.82M | Sep 29, 2025 |
| Commodore Capital Lp | 4.65% | 3,525,000 | 317.25M | Sep 29, 2025 |
| Deerfield Management Company, L.P | 4.02% | 3,046,916 | 274.22M | Sep 29, 2025 |
| HBK Investments L P | 3.76% | 2,850,000 | 256.50M | Sep 29, 2025 |
| FMR, LLC | 3.71% | 2,810,935 | 252.98M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.84% | 640,000 | 57.60M | Oct 30, 2025 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.82% | 620,890 | 55.88M | Sep 29, 2025 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 0.78% | 593,000 | 53.37M | Oct 30, 2025 |
| Columbia Funds Series Trust I-Columbia Cornerstone Growth Fund | 0.67% | 509,004 | 45.81M | Oct 30, 2025 |
| SmallCap World Fund Inc | 0.65% | 491,244 | 44.21M | Sep 29, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.54% | 412,869 | 37.16M | Oct 30, 2025 |